Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Viking Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
0
0
0
0
0
0
Research and development
9
13.7
19
23.6
31.9
45
54.2
63.8
102
345
General and administrative
4.85
5.33
7.12
9.13
10.7
10.7
16.1
37
49.3
48.4
Operating expenses
13.8
19.1
26.2
32.7
42.7
55.7
70.4
101
151
393
Operating income
-13.8
-19.1
-26.2
-32.7
-42.7
-55.7
-70.4
-101
-151
-393
Other non-operating income
-0.88
-1.51
4.1
6.91
3.17
0.69
1.49
14.9
41
33.7
Pre-tax income
-85.9
-110
-360
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
-14.7
-20.6
-22.1
-25.8
-39.5
-55
-68.9
-85.9
-110
-360
EPS, basic
-0.90
-0.79
-0.38
-0.36
-0.54
-0.71
-0.90
-0.91
-1.01
-3.19
EPS, diluted
-0.90
-0.79
-0.38
-0.36
-0.54
-0.71
-0.90
-0.91
-1.01
-3.19
Shares, basic (weighted)
16.3
26
57.6
72
72.6
77.2
76.8
94.3
109
113
Shares, diluted (weighted)
16.3
26
57.6
72
72.6
77.2
76.8
94.3
109
113
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.08
8.99
24.8
8.38
29.1
26.4
36.6
55.5
26.7
166
Short-term investments
11.6
277
267
219
176
119
307
876
540
Other current assets
0.28
0.39
0.28
0.41
0.44
0.62
3.41
2.52
1.13
1.81
Total current assets
14
21.9
302
284
256
211
167
367
907
716
Lease right-of-use assets
0.6
0.32
0.03
1.42
1.13
1
0.09
Total assets
14.5
22.1
302
284
257
211
169
368
908
716
Accounts payable
1.2
1.53
0.96
2.43
3.99
1.44
8.53
7.51
9.81
53.3
Total current liabilities
6.48
8.66
4.55
6.78
12.1
8.78
21.9
19.1
27.4
76.7
Lease liabilities
0.36
0.03
1.26
0.94
0.63
0
Total liabilities
6.49
8.66
4.56
7.14
12.2
8.78
23.2
20.1
28
76.7
Paid-in capital
68.3
94.3
401
406
413
426
445
734
1,369
1,486
Retained earnings
-60.3
-80.9
-103
-129
-168
-223
-292
-378
-488
-848
Treasury stock
-6.8
-6.8
0
0
Shareholders' equity
8.04
13.5
298
277
244
202
145
348
880
639
Total equity
8.04
13.5
298
277
244
202
145
348
880
639
Total liabilities and equity
14.5
22.1
302
284
257
211
169
368
908
716
Shares outstanding
20.8
35.8
71.7
72.4
73.2
78.2
78.3
100
112
115
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-14.7
-20.6
-22.1
-25.8
-39.5
-55
-68.9
-85.9
-110
-360
Stock-based compensation
1.79
1.45
2.61
3.74
5.82
6.1
8.67
16.8
29.7
40.8
Change in payables
0.68
0.26
-0.51
1.47
1.56
-2.54
7.09
-1.02
2.3
43.4
Cash from operations
-11.1
-14.8
-18.8
-24.8
-21.8
-47.6
-48.4
-73.4
-87.8
-279
Purchases of investments
-16.9
-22.5
-348
-362
-281
-168
-121
-478
-1,113
-418
Sales and maturities of investments
20
20.8
82.5
370
322
206
176
299
560
759
Cash from investing
3.03
-1.73
-266
7.46
41.6
38
54.8
-179
-553
341
Stock issued
11.5
22.4
297
0.2
0.21
0.35
0
6.4
10.4
Share buybacks
-0
-6.8
Cash from financing
10.3
22.4
300
0.89
0.95
6.88
4.16
271
612
76.4
Net change in cash
2.31
5.91
15.8
-16.4
20.7
-2.75
10.5
18.9
-28.7
139
Interest paid
0.21
0.12
0.08
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $35.56 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-131.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-102.5%
Net income / average total assets.
Return on invested capital (ROIC)
-156.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-27.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
63.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
21.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-21.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
61.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
22.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
13.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
9.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.72x
Current assets / current liabilities.
Quick ratio
4.57x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.57x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$3.60
Cash from operations / diluted weighted shares.
Book value per share
$3.50
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
10.2x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
10.2x
Market cap / tangible book value, when positive.
Earnings yield
-12.9%
Net income / market cap (the inverse of P/E).
What was Viking Therapeutics, Inc.'s revenue in fiscal 2025?
Viking Therapeutics, Inc. reported revenue of $0.0 for fiscal 2025.
Was Viking Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $359.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.